Bimekizumab ELISA Kit

Catalog No.

KDH28802

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.31-5 μg/mL

Sensitivity

0.156 μg/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

CDP4940, UCB-4940, UCB4940, CAS: 1418205-77-2

Background

Bimekizumab is an investigational humanized IgG1 monoclonal antibody in development for the treatment of moderate to severe plaque psoriasis in adults. Bimekizumab is designed to selectively and directly inhibit both IL-17A and IL-17F, two key cytokines driving the inflammatory process in plaque psoriasis.

A network meta-analysis study of monotherapies for hidradenitis suppurativa: analyses of the current evidence base., PMID:40464762

[Not Available]., PMID:40417903

Biologic and Non-Biologic Therapies for Scalp Psoriasis: A Network Meta-analysis of Randomized Controlled Trials., PMID:40401874

Biologic therapies and small molecules in the treatment of hidradenitis suppurativa., PMID:40373949

Correction to: The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis)., PMID:40373079

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)., PMID:40372625

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)., PMID:40358828

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., PMID:40347389

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., PMID:40323371

Editor's Highlights-June 2025., PMID:40322884

Emerging manifestations of IL-17 immunomodulation in the gastrointestinal tract., PMID:40319948

Antifungal Prophylaxis and Effective Therapy With Bimekizumab in a Patient With Multiresistant Plaque Psoriasis and Recurrent Candidiasis., PMID:40304262

Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial., PMID:40286813

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis., PMID:40276786

The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials., PMID:40268126

Acne Conglobata and Bimekizumab., PMID:40266588

Active Switch From a Single Dose of Bimekizumab to Risankizumab in Psoriasis: A Pilot Study., PMID:40260930

Bimekizumab as-needed dosing in patients with psoriasis: a case series., PMID:40256854

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events., PMID:40242569

Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience., PMID:40228172

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies., PMID:40194794

Wolf's Isotopic Response: A Rare Case of Terra Firma-Forme Dermatosis on Resolved Psoriatic Plaques., PMID:40189743

Psychometric Validation and Interpretation Thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) Questionnaire Using Pooled Data from the Phase 3 BE HEARD I & II Trials of Bimekizumab in Hidradenitis Suppurativa., PMID:40172122

[Hidradenitis suppurativa]., PMID:40171910

Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector., PMID:40156698

Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data., PMID:40153232

[Hot Topics 2024 and 2025 in dermatology]., PMID:40145186

An updated safety review of Hidradenitis Suppurativa treatment options., PMID:40125932

Bimekizumab for Psoriasis: Raising the Bar in Treatment., PMID:40116174

Short-Term Biologic Therapy for Guttate Psoriasis: Successful Treatment with Bimekizumab and Literature Review., PMID:40113443

Long-term maintenance of responses to bimekizumab treatment in moderate-to-severe psoriasis: A real-world comparison of Q4W versus Q8W dosing or bio-naïve versus bio-switched patients., PMID:40087893

Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block., PMID:40076933

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials., PMID:40062409

Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient., PMID:40016589

Efficacy and Safety of Interleukin-17 and Janus Kinase Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis., PMID:40010328

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study., PMID:39982649

A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab., PMID:39980236

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience., PMID:39969045

Response to Sood et al's "Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"., PMID:39956201

Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review"., PMID:39955006

Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions., PMID:39946257

Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis., PMID:39945386

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics., PMID:39925216

Bimekizumab: A novel FDA approved dual IL-17 A/F inhibitor for moderate to severe psoriasis., PMID:39912180

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study., PMID:39900871

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies., PMID:39892885

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension., PMID:39890205

Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges., PMID:39887706

Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders., PMID:39875232

Hidradenitis suppurativa., PMID:39862870

Document Download

Bimekizumab ELISA Kit.pdf